Skip to main content
. 2024 Jun 30;36(3):282–297. doi: 10.21147/j.issn.1000-9604.2024.03.05

Figure 4.

Figure 4

Difference of gene variations between HRD+ and HRD− NSCLC patients with/without EGFR or ALK mutation. (A) The most significant different (P<0.05) gene alterations between HRD+ and HRD− patients with mutant EGFR or ALK; (B) The most significant different (P<0.05) gene alterations between HRD+ and HRD− patients with wide-type EGFR or ALK. HRD−, HRD-negative; HRD+, HRD-positive; HRD, homologous recombination defect; NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; KEGG, Kyoto Encyclopedia of Genes and Genomes.